Prevalence and Prognostic Significance of Main Metabolic Risk Factors in Primary Biliary Cholangitis: a Retrospective Cohort Study of 789 Patients

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Nov 29

PMID 38027142

Authors

Dan-Tong Zhao

Hui-Ping Yan

Ying Han

Wei-Ming Zhang

Yan Zhao

Hui-Yu Liao

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic risk factors in primary biliary cholangitis (PBC) have not been well described in China. Additionally, it is unclear whether these factors have an impact on the prognosis of PBC patients. Therefore, this study aimed to investigate the prevalence of main metabolic risk factors in PBC, and to evaluate their prognostic values for liver-related outcomes.

Methods: A cohort of 789 PBC patients was retrospectively studied between July 2008 and September 2019 by investigating the main metabolic risk factors and analyzing liver-related outcomes.

Results: At presentation, 271 (34.3%) patients had concomitant hyperlipidemia, 126 (16.0%) had hypertension, 94 (11.9%) had type 2 diabetes mellitus (T2DM), and 17 (2.2%) had nonalcoholic fatty liver disease (NAFLD). Hyperlipidemia was found to be associated with the lower risk of liver-related death [<0.0001, hazard ratio (HR): 0.397, 95% confidence interval (CI): 0.268-0.588] and adverse outcomes (<0.0001, HR: 0.487, 95% CI:0.367-0.646), while hypertension was noted as a risk factor for liver-related death (=0.001, HR: 1.788, 95% CI:1.268-2.521) and adverse outcomes (=0.014, HR: 1.417, 95% CI:1.074-1.869). Moreover, age ≥ 55 years old (=0.005) and cirrhosis (<0.0001) had superimposition effects on hypertension as a risk factor for liver-related death, while only cirrhosis (<0.0001) had an effect on hypertension as a risk factor for adverse outcomes. Additionally, anti-sp100 was associated with adverse outcomes (=0.013) in PBC patients with hypertension in univariate Cox regression analysis.

Conclusion: Hyperlipidemia, hypertension, and T2DM were found as main metabolic risk factors in PBC in China. Hyperlipidemia indicated a benign clinical outcome of PBC, while hypertension indicated a poor outcome of PBC. Older age and cirrhosis had superimposition effects on hypertension for liver-related poor outcomes. Anti-sp100 might be associated with adverse outcomes, especially in PBC patients with hypertension.

Citing Articles

Association between diabetes mellitus and primary biliary cholangitis: a two-sample Mendelian randomization study.

Lv D, Wang H, Leng Y, Chen S, Sun H, Meng X Front Endocrinol (Lausanne). 2024; 15:1362584.

PMID: 38774228 PMC: 11106416. DOI: 10.3389/fendo.2024.1362584.

Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review.

Greco S, Campigotto M, DAmuri A, Fabbri N, Passaro A J Clin Med. 2024; 13(9).

PMID: 38731243 PMC: 11084647. DOI: 10.3390/jcm13092714.

References

Zeng N, Duan W, Chen S, Wu S, Ma H, Ou X . Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. Hepatol Int. 2019; 13(6):788-799. DOI: 10.1007/s12072-019-09984-x. View

Han Y, Shi J, Ma A, Xu Y, Ding X, Fan J . Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig. 2013; 34(1):1-7. DOI: 10.1007/s40261-013-0136-3. View

Elkrief L, Rautou P, Sarin S, Valla D, Paradis V, Moreau R . Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016; 36(7):936-48. DOI: 10.1111/liv.13115. View

Moller S, Henriksen J, Bendtsen F . Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol. 2003; 284(6):G970-9. DOI: 10.1152/ajpgi.00521.2002. View

Younossi Z, Bernstein D, Shiffman M, Kwo P, Kim W, Kowdley K . Diagnosis and Management of Primary Biliary Cholangitis. Am J Gastroenterol. 2018; 114(1):48-63. DOI: 10.1038/s41395-018-0390-3. View

Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D . Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. 2006; 55(12):1795-800. PMC: 1856484. DOI: 10.1136/gut.2005.079814. View

Nikkila K, Hockerstedt K, Miettinen T . High cholestanol and low campesterol-to-sitosterol ratio in serum of patients with primary biliary cirrhosis before liver transplantation. Hepatology. 1991; 13(4):663-9. View

Lindor K, Bowlus C, Boyer J, Levy C, Mayo M . Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 69(1):394-419. DOI: 10.1002/hep.30145. View

Iluz-Freundlich D, Uhanova J, Grubert Van Iderstine M, Minuk G . The impact of primary biliary cholangitis on non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2020; 33(4):565-570. PMC: 7908858. DOI: 10.1097/MEG.0000000000001782. View

10.

Angulo P, Keach J, Batts K, Lindor K . Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999; 30(6):1356-62. DOI: 10.1002/hep.510300604. View

11.

Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H . Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020; 369:m997. PMC: 7186854. DOI: 10.1136/bmj.m997. View

12.

. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017; 67(1):145-172. DOI: 10.1016/j.jhep.2017.03.022. View

13.

Crippin J, Lindor K, Jorgensen R, Kottke B, Harrison J, Murtaugh P . Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?. Hepatology. 1992; 15(5):858-62. DOI: 10.1002/hep.1840150518. View

14.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

15.

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

16.

Rigopoulou E, Davies E, Pares A, Zachou K, Liaskos C, Bogdanos D . Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut. 2005; 54(4):528-32. PMC: 1774444. DOI: 10.1136/gut.2003.036558. View

17.

Selmi C, Bowlus C, Gershwin M, Coppel R . Primary biliary cirrhosis. Lancet. 2011; 377(9777):1600-9. DOI: 10.1016/S0140-6736(10)61965-4. View

18.

Zhao D, Liao H, Liu Y, Zhao Y, Feng X, Yan H . Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients. Dig Dis Sci. 2011; 56(9):2750-7. DOI: 10.1007/s10620-011-1661-7. View

19.

Chen S, Duan W, Li M, Li S, Lv T, Tian Q . Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. J Gastroenterol Hepatol. 2018; 34(7):1236-1241. DOI: 10.1111/jgh.14521. View

20.

Longo M, Crosignani A, Battezzati P, Squarcia Giussani C, Invernizzi P, Zuin M . Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002; 51(2):265-9. PMC: 1773333. DOI: 10.1136/gut.51.2.265. View